R 0010/13 (Fundamental violation of Article 113 EPC) of 10.2.2014

European Case Law Identifier: ECLI:EP:BA:2014:R001013.20140210
Date of decision: 10 February 2014
Case number: R 0010/13
Petition for review of: T 1760/11
Application number: 00108480.5
IPC class: C07D 401/12
A61K 31/44
A61P 1/04
Language of proceedings: EN
Distribution: B
Download and more information:
Decision text in EN (PDF, 223 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Magnesium salt of the (-)-enantiomer of omeprazole and its use
Applicant name: AstraZeneca AB
Opponent name: Hexal AG
Teva Pharmaceutical Industries Ltd.
Mepha AG
STADA Arzneimittel AG
Pinewood Laboratories Limited
ETHYPHARM
Actavis Group hf.
Lupin Limited
Zentiva a.s.
Generics [UK] Limited
Ratiopharm GmbH
1A Pharma GmbH / Hexal Pharma GmbH
Hörnchen, Ulrich, Dr.
Board: EBA
Headnote: -
Relevant legal provisions:
European Patent Convention Art 56
European Patent Convention Art 112(1)(a)
European Patent Convention Art 112a(2)
European Patent Convention Art 112a(2)(c)
European Patent Convention Art 112a(4)
European Patent Convention Art 113(1)
European Patent Convention R 106
European Patent Convention R 107
European Patent Convention R 109(2)(a)
Keywords: Fundamental violation of the right to be heard (no)
Clearly inadmissible
Clearly unallowable
List of grounds exhaustive
Obligation to raise objection
Sufficiently reasoned (yes)
Catchwords:

-

Cited decisions:
R 0001/08
R 0002/08
R 0009/08
R 0010/09
R 0003/10
R 0009/10
R 0013/11
R 0019/11
T 0967/97
T 0778/98
T 0401/04
T 1154/04
T 0021/08
Citing decisions:
R 0006/17

22 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

EPC Implementing Rules

Case Law Book: I Patentability

General Case Law